Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a clinical trial.

The purpose of this study was to assess the acute effects of methylene blue, an inhibitor of nitric oxide synthesis, on hemodynamics and gas exchange in patients with refractory septic shock in a prospective clinical trial at medical and surgical intensive care units in a tertiary university hospital.

Who Took Part

According to the abstract, 10 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Prospective, sequential study of 10 consecutive patients admitted with severe septic shock of diverse causes and unable to achieve an adequate arterial pressure despite the use of at least two vasoactive drugs.

How the Study Was Run

Six of them also developed acute lung injury.

Hemodynamic and respiratory parameters were measured at baseline and at 30, 60, 120, and 180 minutes after the bolus injection.

What Was Measured

PubMed files the paper under topics including Hemodynamics, Methylene Blue, Nitric Oxide, Pulmonary Gas Exchange, Respiratory Distress Syndrome and Shock, Septic.

What This Means in Plain Language

This is a clinical trial of Methylene blue (non-peptide stack partner) in 10 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1998 (Journal of critical care), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.